Stock Fundamentals

Company Information

Company Name
Nurix Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US67080M1036
CIK: 0001549595
CUSIP: 67080M103
Currency: USD
Full Time Employees: 317
Phone: 415 660 5320
Fiscal Year End: November
IPO Date: Jul 24, 2020
Description:

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.

Address:

1600 Sierra Point Parkway, Brisbane, CA, United States, 94005

Directors & Officers

Name Title Year Born
Dr. Arthur T. Sands M.D., Ph.D. CEO, President & Director 1962
Mr. Johannes Van Houte Chief Financial Officer 1967
Dr. Gwenn M. Hansen Ph.D. Chief Scientific Officer 1971
Dr. Christine Ring J.D., Ph.D. Chief Legal Officer, Secretary & Chief Compliance Officer 1965
Dr. John Kuriyan Ph.D. Founder & Member of Scientific Advisory Board NA
Dr. Arthur Weiss M.D., Ph.D. Founder & Member of Scientific Advisory Board NA
Rita Kwong Senior Accounting Manager NA
Dr. Pasit Phiasivongsa Ph.D. Chief Technical Officer NA
Dr. Jason Kantor Ph.D. Chief Business Officer NA
Mr. Christopher B. Phelps Ph.D. Senior VP & Head of Early Drug Discovery NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Jan 30, 2026 Gwenn Hansen N/A Sale 4.90K $16.60 $81.26K
Jan 30, 2026 Houte Hans Van N/A Sale 3.66K $16.60 $60.77K
Nov 03, 2025 Houte Hans Van N/A Sale 6.28K $12.56 $78.93K
Oct 30, 2025 Gwenn Hansen N/A Sale 4.09K $12.80 $52.31K
Oct 30, 2025 Houte Hans Van N/A Sale 3.13K $12.80 $40.06K
Aug 01, 2025 Houte Hans Van N/A Sale 5.40K $11.03 $59.58K
Jul 30, 2025 Gwenn Hansen N/A Sale 4.31K $12.01 $51.74K
Jul 30, 2025 Houte Hans Van N/A Sale 4.30K $12.01 $51.69K
May 02, 2025 Houte Hans Van N/A Sale 6.20K $11.33 $70.22K
Apr 30, 2025 Gwenn Hansen N/A Sale 3.38K $11.50 $38.84K
Apr 30, 2025 Houte Hans Van N/A Sale 2.44K $11.50 $28.04K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
BlackRock Inc 8.93M Mar 31, 2026 8.63% $0.00 0.57%
Redmile Group, LLC 7.73M Mar 31, 2026 7.48% $7.94 -4.46%
Vestal Point Capital LP 6.50M Mar 31, 2026 6.29% $2.82 38.59%
Deep Track Capital, LP 6.35M Mar 31, 2026 6.14% $1.61 -9.82%
Vanguard Group Inc 5.95M Dec 31, 2025 5.75% $0.00 32.54%
FMR Inc 5.54M Mar 31, 2026 5.36% $0.00 30.87%
State Street Corp 5.14M Mar 31, 2026 4.97% $0.00 44.44%
Morgan Stanley - Brokerage Accounts 4.93M Mar 31, 2026 4.77% $0.00 1.04%
Baker Bros Advisors LP 4.66M Mar 31, 2026 4.51% $0.41 0.00%
Vanguard Capital Management, LLC 4.43M Mar 31, 2026 4.28% $0.00 0.00%
General Atlantic Llc 4.10M Mar 31, 2026 3.97% $2.96 -16.24%
Perceptive Advisors LLC 3.71M Mar 31, 2026 3.59% $1.12 4.36%
T. Rowe Price Associates, Inc. 3.29M Mar 31, 2026 3.18% $0.01 1.29%
Pictet Asset Manangement SA 2.73M Mar 31, 2026 2.64% $0.04 -21.38%
Geode Capital Management, LLC 2.52M Mar 31, 2026 2.44% $0.00 5.67%
Rubric Capital Management LP 2.47M Mar 31, 2026 2.39% $0.41 0.00%
Deutsche Bank AG 2.30M Mar 31, 2026 2.22% $0.01 -7.71%
COMMODORE CAPITAL LP 2.28M Mar 31, 2026 2.20% $2.04 0.00%
BRAIDWELL LP 1.75M Mar 31, 2026 1.69% $0.91 -19.83%
Trails Edge Capital Partners, LP 1.74M Mar 31, 2026 1.69% $6.19 0.00%

Shares Statistics

Shares Outstanding: 103.41M
Shares Float: 82.41M
% Insiders: 108.70%
% Institutions: 11,494.80%
Short % Float: 18.90%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 3.25M 3.14% ▲ 0.48% Apr 30, 2026
2 State Street® SPDR® S&P® Biotech ETF 3.11M 3.01% ▼ 0.61% May 31, 2026
3 iShares Russell 2000 ETF 2.42M 2.34% ▲ 0.93% May 29, 2026
4 Xtrackers MSCI World Swap ETF 1C 2.14M 2.07% ▼ 0.63% Dec 31, 2025
5 Pictet-Biotech P USD 1.79M 1.73% ▲ 0.40% Feb 28, 2026
6 ARK Genomic Revolution 1.63M 1.57% ▲ 6.31% Mar 31, 2026
7 ARK Genomic Revolution ETF 1.57M 1.52% ▼ 0.26% May 31, 2026
8 Eventide Healthcare & Life Sciences I 1.30M 1.26% ▲ 0.00% Mar 31, 2026
9 Vanguard Institutional Extnd Mkt Idx Tr 1.09M 1.05% ▲ 0.53% Apr 30, 2026
10 Fidelity Small Cap Index 996.66K 0.96% ▲ 1.58% Mar 31, 2026

Valuation Metrics

Enterprise Value: $1.27B
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

Market Cap: $1.75B
EBITDA: $-307.31M
Book Value: $4.65
Earnings/Share: $-3.17
Profit Margin: 0.00%
Operating Margin: -1,479.45%
ROA (TTM): -31.50%
ROE (TTM): -61.40%
Revenue (TTM): $71.78M
Revenue/Share (TTM): $0.77
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -66.10%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-11-30 7.02x 0.01x 0.22x N/A -0.01x
2024-11-30 6.46x 0.02x 0.21x N/A -0.04x
2023-11-30 3.40x 0.04x 0.44x N/A -0.05x
2022-11-30 4.51x 0.02x 0.27x -12.84x -0.03x
2021-11-30 4.70x 0.01x 0.28x -17.07x -0.03x
2020-11-30 6.70x 0.03x 0.27x -19.19x -0.12x
2019-11-30 2.44x -0.08x 1.22x -28.65x -0.23x
2018-11-30 1.24x -0.08x 0.75x -11.91x -0.42x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about NRIX.US!